Expert Interview
A Third Look: Discussing the Phase I clinical data for RO7589831, a first-in-class Werner helicase inhibitor developed by Roche, presented as an abstract at the 2025 AACR Annual Meeting.
Ticker(s): RHHBY- Staff medical oncologist in SCPMG (Southern California Permanent Medical Group, Kaiser San Diego)
- Has seen over 30 + patients with DLBCL
- Has prescribed Monjuvi once or twice and recommended it
- Cancer specialist trained in blood disorders and the medical treatment of malignancies.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
